Prestige Consumer Healthcare (NYSE:PBH) Issues FY 2027 Earnings Guidance

Prestige Consumer Healthcare (NYSE:PBH) updated its FY 2027 earnings guidance on Wednesday. The company provided earnings per share guidance of 4.420-4.510 for the period, compared to the consensus earnings per share estimate of 4.790. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.2 billion.

Prestige Consumer Healthcare Stock Performance

Prestige Consumer Healthcare stock traded up $1.34 on Wednesday, reaching $51.75. 749,859 shares of the stock were exchanged, compared to its average volume of 477,997. The company has a current ratio of 3.11, a quick ratio of 1.93 and a debt-to-equity ratio of 0.58. Prestige Consumer Healthcare has a twelve month low of $49.28 and a twelve month high of $89.37. The firm has a fifty day moving average price of $59.12 and a two-hundred day moving average price of $61.68. The stock has a market cap of $2.45 billion, a PE ratio of 13.69, a PEG ratio of 1.52 and a beta of 0.40.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Wednesday, May 13th. The company reported $1.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.39 by ($0.16). The business had revenue of $281.62 million during the quarter, compared to analyst estimates of $293.64 million. Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. Sell-side analysts anticipate that Prestige Consumer Healthcare will post 4.54 EPS for the current year.

Analysts Set New Price Targets

PBH has been the topic of several recent analyst reports. Oppenheimer cut their price target on Prestige Consumer Healthcare from $77.00 to $65.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Jefferies Financial Group lowered their price objective on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a research note on Friday, January 30th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Tuesday, April 21st. Three research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $74.75.

Insider Buying and Selling

In other news, VP Jeffrey Zerillo sold 1,207 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total transaction of $66,372.93. Following the sale, the vice president owned 42,820 shares of the company’s stock, valued at approximately $2,354,671.80. This trade represents a 2.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Squarepoint Ops LLC increased its holdings in Prestige Consumer Healthcare by 316.1% in the 3rd quarter. Squarepoint Ops LLC now owns 301,866 shares of the company’s stock valued at $18,836,000 after buying an additional 229,311 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Prestige Consumer Healthcare by 28.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock worth $46,997,000 after acquiring an additional 120,965 shares during the period. Bank of America Corp DE boosted its position in shares of Prestige Consumer Healthcare by 19.1% during the 2nd quarter. Bank of America Corp DE now owns 721,371 shares of the company’s stock valued at $57,601,000 after acquiring an additional 115,459 shares in the last quarter. Man Group plc acquired a new stake in shares of Prestige Consumer Healthcare during the 3rd quarter valued at about $6,808,000. Finally, Raymond James Financial Inc. increased its stake in Prestige Consumer Healthcare by 15.7% in the third quarter. Raymond James Financial Inc. now owns 637,932 shares of the company’s stock valued at $39,807,000 after acquiring an additional 86,373 shares during the period. 99.95% of the stock is owned by institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).